Cost of Musculoskeletal Diseases: Impact of Work Disability and Functional Decline

Journal of Rheumatology

Volumn 30, Issue SUPPL. 68, 2003, Pages 8-11

  Yelin, Edward ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTHRITIS; CONFERENCE PAPER; COST OF ILLNESS; DISABILITY; EMPLOYMENT; FUNCTIONAL ASSESSMENT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; INCOME; LOW BACK PAIN; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; DAILY LIFE ACTIVITY; ECONOMICS; FEMALE; MALE; PATHOPHYSIOLOGY; REVIEW; RHEUMATOLOGY; SOCIAL PSYCHOLOGY; STATISTICS; UNITED STATES;

ACTIVITIES OF DAILY LIVING; DISABILITY EVALUATION; ECONOMICS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MUSCULOSKELETAL DISEASES; PREJUDICE; RHEUMATOLOGY; UNITED STATES;

EID: 1642286897     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Rice D. Estimating the cost of illness. Hyattsville, MD: National Center for Health Statistics, Health Economic Series; 1966: No. 6.
2. Cooper B, Rice D. The economic cost of illness revisited. Social Security Bulletin 1979;39:21-35.
3. Rice D, Hodgson T, Kopstein A. The economic costs of illness: A replication and update. Health Care Finance Rev 1985;7:61-80.
4. Rice D. The economic burden of musculoskeletal conditions, 1995. In: Praemer A, Furner S, Rice D, editors. Musculoskeletal conditions in the United States. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1999.
5. Cohen S. Sample design of the 1996 Medical Expenditure Panel Survey Household Component. Rockville, Maryland: Agency for Health Care Policy and Research, AHCPR Publication No. 97-0027; 1997.
6. Cohen S. Sample design of the 1997 Medical Expenditure Panel Survey Household Component. Rockville, Maryland: Agency for Healthcare Research and Quality, AHRQ Publication No. 01-0001; 2000.
7. Agency for Healthcare Research and Quality. MEPS household component 1996 full year use and expenditure data: Public use documentation, C6-C 11. Rockville, Maryland: Agency for Healthcare Research and Quality; 1999.
8. Yelin E, Cisternas M, Pasta D, Trupin L. Direct and indirect costs of musculoskeletal conditions in 1997: absolute and incremental estimates. Atlanta: Centers for Disease Control and Prevention; 2003.
9. Yelin E, Katz P, Lubeck D, Wanke L, Buatti M. Impact of etanercept (Enbrel) on health care use and employment in early RA [abstract]. Arthritis Rheum 2001;44 Suppl: S152.
10. Yelin E. The worldwide economic and functional impact of rheumatic disease. In: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M, editors. Rheumatology. 3rd ed. London: Mosby, (in press).
11. Pugner K, Scott D, Holmes J, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29:305-20.
12. Yelin E, Wanke L. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
13. Messer J, Michaud K, Choi H, Wolfe F. Lifetime direct medical costs of rheumatoid arthritis [abstract]. Arthritis Rheum 2002;46 Suppl:S581.
14. Cohen S, Wooley J, Chan W. Interleukin-1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J Rheumatol 2003;30:225-31.
15. Lipsky P, van der Heijde D, St. Clair E, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
16. Bresnihan B, Alvaro-Gracia J, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998:41:2196-204.
17. Mathias S, Colwell H, Miller D, Moreland L, Buatti M, Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000;22:129-39.
18. Puolakka K, Kautiainen H, Mottonen T, et al. Initial aggressive drug treatment with DMARDs prevents work disability in early rheumatoid arthritis [abstract]. Arthritis Rheum 2002;46 Suppl:S375.
19. Bresnihan B, Chan W, Woolley J. Increase in productivity after six and twelve months of anakinra treatment in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2001;44 Suppl:S77.
20. Sutcliffe N, Clarke A, Taylor R, Frost C, Isenberg D. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology Oxford 2001;40:37-47.
21. Maetzel A, Li L. The economic burden of low back pain: a review of studies published between 1996 and 2001. Best Pract Res Clin Rheumatol 2002;16:23-30.
22. Gabriel S, Crowson C, Campion M, O'Fallon W. Direct medical costs unique to people with arthritis. J Rheumatol 1997;24:719-25.
23. Gabriel S, Crowson C, Campion M, O'Fallon W. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997;24:43-8.
24. Allaire S, DeNardo B, Szer I, et al. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol 1992;19:952-5.
25. Yelin E, Callahan L. Musculoskeletal conditions in the US. Arthritis Rheum 1995;38:1351-66.
26. Praemer A, Furner S, Rice D, editors. Musculoskeletal conditions in the United States. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1999.